SCHEMBL4773151

SCHEMBL4773151

NC(=O)c1cccc(CCS(=O)(=O)Nc2ccc(C(=O)NCc3ccc(C(F)(F)F)nc3)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
ITK Q08881 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ALDH1A1 P00352 1/20 0.42
NAMPT P43490 3/20 0.41
SCN3A Q9NY46 2/20 0.41
CA2 P00918 2/20 0.41
AURKA O14965 2/20 0.41
AURKB Q96GD4 2/20 0.41
CA1 P00915 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CNR2 P34972 1/20 0.40
RPS6KB1 P23443 1/20 0.40
VNN1 O95497 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776425 0.84 TDP1 (0.42) MAPTMEN1KMT2ALMNATDP1
SCHEMBL4777709 0.84 PPARG (0.48) MAPTMEN1KMT2ALMNATDP1
SCHEMBL4777334 0.84 SCN3A (0.46) MAPTMEN1KMT2ALMNATDP1
SCHEMBL4767854 0.81 MAPT (0.46) MAPTMEN1KMT2ALMNATDP1
SCHEMBL4773250 0.81 SCN3A (0.51) MEN1KMT2ATDP1ITKALDH1A1
SCHEMBL4768151 0.81 MAPT (0.49) MAPTMEN1KMT2ATDP1ITK
SCHEMBL5572196 0.80 PPARA (0.42) MAPTMEN1KMT2ALMNATDP1
SCHEMBL4773154 0.79 GAA (0.55) MAPTMEN1KMT2ALMNANPSR1
SCHEMBL5571585 0.78 MAPK14 (0.44) MAPTMEN1KMT2ALMNATDP1
SCHEMBL4774976 0.77 ITK (0.46) MAPTMEN1KMT2ALMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 MAPT 294/4885MEN1 1302/4885KMT2A 1501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.